Orakl Oncology combines data and biology to bring new drugs to cancer patients

Cancer incidence is on the rise, particularly among younger adults, but most new drug compounds fail to progress through clinical trials. According to French entrepreneur Fanny Jaulin (on the right in the picture above), the problem lies with clinical trial design.  Learn more about your ad choices. Visit podcastchoices.com/adchoices